Boehringer Ingelheim: New sub-analyses to be presented at ESC Congress 2018 further support positive safety profile of Pradaxa® (dabigatran etexilate)
Boehringer Ingelheim today announced that it will present nine sub-analyses from the RE-DUAL PCITM trial and GLORIATM-AF Registry Program at the upcoming ESC Congress 2018, organised by the European Society of Cardiology, taking place in Munich, Germany on the 25-29 August 2018. The primary data from these studies have contributed to a positive label update for dabigatran etexilate (Pradaxa®) in the European Union (EU).
The primary RE-DUAL PCITM trial investigated anticoagulation in patients with non-valvular atrial fibrillation (AF) following percutaneous coronary intervention (PCI) and stent placement. Data showed significantly lower rates of major or clinically relevant non-major bleeding events for dual therapy with dabigatran etexilate when compared to triple therapy with warfarin without compromise on efficacy.1,2
GLORIATM-AF is a large, prospective, observational study program run in over 40 countries worldwide. The primary analysis of nearly 5000 AF patients treated with dabigatran etexilate showed that the rates of stroke, major bleeding and life-threatening bleeding were low, confirming the sustained safety and effectiveness of dabigatran etexilate over two years of follow-up in clinical practice.3 These data are consistent with the long-term safety profile observed in other real-world evidence studies, as well as in randomised clinical trials.3
Both studies have helped to further confirm the safety profile of dabigatran etexilate in high risk patient populations, as well as in a real-world setting. In recognition of this, the European Medicines Agency (EMA) has recently authorised the inclusion of data from both studies within the SmPC for dabigatran etexilate in the EU.4
“Insights from the RE-DUAL PCITM and GLORIATM-AF study data have helped to further inform the positive safety profile of dabigatran etexilate for the treatment of AF patients”, said Waheed Jamal, MD, Corporate Vice President & Head of Cardiometabolic Medicine at Boehringer Ingelheim. “We are pleased to see that the value these studies bring is also acknowledged by the EMA and the medical community. This is reflected by the updates to the EU SmPC and the number of abstracts accepted for presentation at ESC Congress 2018.”
Details of the data presented at ESC Congress 2018 are as follows:
Abstract Title |
Details
|
||
RE-DUAL PCI TM | |||
High body mass index and outcomes of dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor in patients with atrial fibrillation undergoing PCI: Results from RE-DUAL PCITM |
SPAF-A346 (1160.186)
|
||
The effect of age on the efficacy and safety of dabigatran dual therapy in atrial fibrillation after PCI: a subgroup analysis from the RE-DUAL PCITM |
SPAF-A360 (1160.186)
|
||
The effect of PCI complexity on the efficacy and safety of dabigatran dual therapy vs warfarin triple therapy in atrial fibrillation: a subgroup analysis from the RE-DUAL PCITM trial |
SPAF-A356 (1160.186)
|
||
Dual antithrombotic therapy with dabigatran vs triple therapy with warfarin after PCI in patients with atrial fibrillation and diabetes mellitus (a RE-DUAL PCITM subgroup analysis) |
SPAF-A358 (1160.186)
|
||
GLORIA TM -AF |
|||
Two-year outcomes of dabigatran etexilate treatment in patients with co-morbid heart failure and atrial fibrillation: the GLORIATM-AF registry |
SPAF-A343 (1160.129/136/171)
|
||
Two-year outcomes of dabigatran etexilate in patients with atrial fibrillation with and without a history of coronary artery disease: Data from GLORIATM-AF |
SPAF-A354 (1160.129/136/171)
|
||
When are Atrial Fibrillation Patients at Risk to Discontinue Anticoagulation Treatment? Results from the GLORIATM-AF Registry |
SPAF-A349 (1160.129/136/171)
|
||
A prospective global registry on oral antithrombotic treatment in patients with atrial fibrillation: GLORIATM-AF Phase III baseline characteristics; (1160.129/136/171) |
SPAF-A347 (1160.129/136/171) |
||
Geographic region, stroke risk and renal function strongly affect treatment choice for stroke prevention in patients with non-valvular AF: results from the GLORIATM-AF registry program |
SPAF-A353 (1160.129/136/171)
|
||
Others | |||
Evaluation of VTE-BLEED for predicting intracranial or fatal bleedings in stable anticoagulated patients with venous thromboembolism |
VTE-A72 (Study TBC)
|
||
Safety and Effectiveness of Dabigatran Relative to Warfarin in Routine Care – Final results from a long-term monitoring program; (1160.207) |
SPAF-A357 (1160.207)
|
||
Trauma victims requiring dabigatran reversal with idarucizumab in RE-VERSE AD |
SPAF-A356 (1160.186)
|
||
Making sense of real-world evidence: addressing the uncertainties surrounding anticoagulation for stroke prevention in non-valvular atrial fibrillation |
MAPOR-A42
|
More information on the Boehringer Ingelheim data due to be presented or published at the ESC Congress 2018 can be found here.
Intended audiences:
This press release is issued from our
Corporate Headquarters in Ingelheim, Germany and is intended to provide
information about our global business. It is directed to the
international audience outside Germany. Please be aware that information
relating to the approval status and labels of approved products may vary
from country to country, and a country-specific press release on this
topic may have been issued in the countries where we do business.
For references and notes to editors, please visit: https://www.boehringer-ingelheim.com/press-release/new-data-at-ESC-supports-Pradaxa-safety-profile
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180820005042/en/
Contact information
Boehringer Ingelheim
Corporate Communications
Media
+ PR
Meike Bausinger
Phone: +49 6132 77 182085
Mobile:
+49 151 44061760
Fax: +49 6132 77 6601
Email: press@boehringer-ingelheim.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Delivers a Strong Start to the Year With Record Net Sales of Over 1 Billion USD for the First Quarter and 12.4% Year-on-Year Growth24.4.2024 08:00:00 EEST | Press release
Galderma Group AG (SWX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2024. Record net sales of 1.071 billion USD in the first quarter of 2024, surpassing for the first time the 1 billion USD mark for the first three months in a year Net sales growth for the first quarter of 2024 was 12.4% year-on-year on a constant currency basis1 , primarily driven by volume Broad-based growth across all product categories, with constant currency year-on-year growth of 19.3% for Injectable Aesthetics, 8.4% for Dermatological Skincare, and 4.1% for Therapeutic Dermatology Growth across geographies, especially in International markets while U.S. growth accelerated year-on-year 2024 full year guidance confirmed: 7-10% net sales year-on-year growth at constant currency and Core EBITDA margin in line with 2023 at constant currency Continued execution of Galderma’s integrated dermatology strategy, progressing on its innovation pipeline, comm
FPT Cooperates with USAID to Promote Clean Energy Deployment, Reduce Greenhouse Gas Emissions, and Accelerate Net Zero Transition24.4.2024 07:35:00 EEST | Press release
FPT Corporation signed Letter of Cooperation with the United States Agency for International Development’s (USAID) Vietnam Low Emission Energy Program II (V-LEEP II), with the goal of supporting the corporation in achieving the Net Zero target by 2040, a decade earlier than Vietnam's commitment. FPT is Vietnam’s first technology firm to collaborate with V-LEEP II. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423349833/en/ The signing ceremony was attended by FPT Corporation Senior Executive Vice President Nguyen The Phuong, FPT Software Senior Executive Vice President Nguyen Khai Hoan, and USAID/Vietnam Deputy Mission Director Bradley Bessire (Photo: Business Wire) In accordance with the agreements, V-LEEP II will provide technical assistance to FPT from April 2024 to April 2025 as the corporation formulates a plan to execute its net-zero commitments. This entails providing a comprehensive understanding of Net Zero stra
Binarly Launches Next-Generation Transparency Platform to Elevate Software Supply Chain Security23.4.2024 19:00:00 EEST | Press release
Binarly, provider of an industry leading AI-powered firmware and software supply chain security platform, announces the release of the Binarly Transparency Platform v2.0 with features for continuous post-build compliance, visibility into the security posture of IoT and XIoT devices, and the ability to identify malicious behavior and hidden backdoors within binaries based on their behavior. Learn more here. Based on the company’s proprietary Binary Risk Intelligence technology, the new innovations underscore Binarly's commitment to pioneering solutions that enhance transparency and security across firmware and software ecosystems. Founded in 2021 with a vision to increase transparency in the software supply chain through advanced program analysis, Binarly’s flagship platform has automated the discovery of hundreds of new vulnerabilities, preemptively addressing our customers' security risks before they could escalate. Binarly’s patented approach, powered by modern AI, has proactively ne
Making History: ASPIRE to Launch Inaugural ‘Abu Dhabi Autonomous Racing League’ Redefining Future of Extreme Sport on April 2723.4.2024 18:54:00 EEST | Press release
On Saturday, April 27th, Abu Dhabi will host a groundbreaking event, welcoming 10,000 spectators to witness the inaugural ASPIRE Abu Dhabi Autonomous Racing League (A2RL) at the iconic Yas Marina Circuit. This brand-new autonomous racing competition marks a significant milestone in motorsport history, billed as the largest league of its kind globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423980323/en/ Making History: ASPIRE to Launch Inaugural ‘Abu Dhabi Autonomous Racing League’ Redefining Future of Extreme Sport on April 27 (Photo: AETOSWire) Eight teams will compete: Code19 Racing (one of the first independent autonomous racing entity from the USA), Constructor University (based in Germany and Switzerland), Fly Eagle (representing Beijing Institute of Technology from China and Khalifa University from the UAE), HUMDA Lab (a member of the Széchenyi István University Group from Hungary), KINETIZ (a collaboration
DataXstream Expands into Nordic Region with Successful Go Live for Martin & Servera23.4.2024 16:07:00 EEST | Press release
DataXstream LLC, an SAP solution provider focused on order management and point of sale for sales and distribution, today announced it is expanding into the Nordic region after a successful implementation of its OMS+ platform across two key business units for the Martin & Servera group, Sweden’s leading restaurant and catering distributor that specializes in the needs of the restaurant industry. Learn more about DataXstream OMS+ here. Martin & Servera is a group of companies based in Stockholm who was faced with the challenge of managing multiple ERP systems that were facing end of life, so they decided to consolidate onto a single instance of SAP S/4 HANA for all their business units. As part of this migration, Martin & Servera turned to DataXstream’s OMS+ cross-channel order management platform to help them enable faster order entry and streamline their sales and order processes between all companies within their organization. Working with DataXstream’s LATAM delivery team, Kötthalle
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom